Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Adrenergic Receptors: ɑ Subtype

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Semisynthesis, characterisation, and antibacterial evaluation of a novel lecanoric acid-derived amide library.

Beilstein journal of organic chemistry·2026

Same author

Rationally designed copper-deferiprone-phenanthroline complex as a dual anticancer and SARS-CoV-2 inhibitor.

RSC advances·2026

Same author

Anti-invasive and cytotoxic evaluation of a (+)-pinoresinol-based semisynthetic library against glioblastoma.

Beilstein journal of organic chemistry·2026

Same author

FKBP52 in cancer biology and therapy: molecular mechanisms, signalling networks, and drug targeting of the FKBP protein family.

Biochemical pharmacology·2026

Same author

Phosphorescent Iridium Hydrazinonicotinic Acid (HYNIC) Complexes That Bind to Prostate Specific Membrane Antigen: Potential Photodynamic Therapy of Prostate Cancer.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026

Same author

Steroidal-nitroxide hybrid sustains oxidative stress and enhances cisplatin efficacy in vitro across multiple cancer cell lines.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026

Search research articles

Related Experiment Video

Updated: May 28, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Novel paramagnetic AT1 receptor antagonists.

Nichole P H Tan¹, Michelle K Taylor, Steven E Bottle

¹ARC Centre of Excellence for Free Radical Chemistry and Biotechnology, Victoria, Australia.

Chemical Communications (Cambridge, England)

|October 4, 2011

Summary

This summary is machine-generated.

New paramagnetic selective angiotensin AT(1) receptor antagonists (sartans) with nitroxides show effectiveness in vitro and in vivo. A specific compound protected hypertensive rats against vascular injury, indicating potential therapeutic applications.

More Related Videos

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Related Experiment Videos

Last Updated: May 28, 2026

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

Area of Science:

Medicinal Chemistry
Pharmacology
Cardiovascular Research

Background:

Angiotensin AT(1) receptor antagonists (sartans) are crucial in managing hypertension and related cardiovascular diseases.
Developing novel sartans with enhanced properties, such as paramagnetic capabilities, is an active area of research.
Nitroxide-containing compounds offer unique properties for potential therapeutic and diagnostic applications.

Purpose of the Study:

To synthesize and characterize novel paramagnetic selective angiotensin AT(1) receptor antagonists (sartans) incorporating nitroxide moieties.
To evaluate the in vitro and in vivo pharmacological activity of these novel sartan compounds.
To assess the potential of these compounds in protecting against vascular injury in a hypertensive rat model.

Main Methods:

Synthesis of novel paramagnetic sartan compounds bearing nitroxides.
In vitro pharmacological evaluation of receptor antagonist activity, including pK(B) determination.
In vivo assessment of vascular injury protection in hypertensive rats using a carotid artery balloon injury model.

Main Results:

Novel paramagnetic selective angiotensin AT(1) receptor antagonists (sartans) were successfully prepared.
Compounds demonstrated effective sartan activity with pK(B) values ranging from 6.2 to 9.1.
The sodium salt of one compound significantly protected against vascular injury and attenuated intimal thickening in hypertensive rats.

Conclusions:

The synthesized nitroxide-bearing sartans are effective angiotensin AT(1) receptor antagonists.
These novel compounds exhibit potential in mitigating vascular injury associated with hypertension.
The development of paramagnetic sartans opens avenues for new cardiovascular therapeutic strategies.